Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.

Trial Details

NCT ID
NCT06130787
Phase
NA
Sponsor
University Hospital, Clermont-Ferrand
Status
RECRUITING
Cancer Type
Chronic Myeloid (CML) Leukemia
Interventions
  • Blood and bone marrow sample
Locations (sample)
  • Annecy, France|45.90878,6.12565
  • Bordeaux, France|44.84124,-0.58046
  • Caen, France|49.18585,-0.35912
  • Clermont-Ferrand, France|45.77969,3.08682
  • Créteil, France|48.79266,2.46569

Key Eligibility Criteria

  • Age ≥18 years
  • CML in chronic phase at time of diagnosis. Diagnosis must be made no more than 3 months (90 days) prior to inclusion. Diagnosis of chronic-phase CM…
  • BCR ::ABL1 transcript quantifiable by quantitative PCR
  • 1st-line treatment with tyrosine kinase inhibitor

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Myeloid (CML) Leukemia Trials on Trialify →